Live News EQUITY FLASH L impact Oct 26, 2026, 10:07 AM UTC Nanobiotix reports response rate in Phase 1 melanoma study Nanobiotix reported a response rate in a Phase 1 study involving resistant melanoma. SquawkNews Desk